News Releases | Olink Holding AB

Date	Title
Sep 19, 2023	Announcing the Olink® Target 48 Mouse Cytokine Panel – the next generation in immunoassays designed to accelerate translational research.
Sep 12, 2023	Eurofins Genomics adopts Olink® technology to advance proteomics research and accelerate precision medicine programs
Aug 29, 2023	Olink to participate in September investor events
Aug 09, 2023	Olink reports second quarter 2023 financial results
Aug 08, 2023	Baylor College of Medicine Human Genome Sequencing Center adopts Olink® Explore HT proteomics platform
Jul 13, 2023	Olink to report second quarter 2023 financial results on August 9, 2023, and to participate in the Canaccord Genuity 43rd Annual Growth Conference
Jul 12, 2023	Announcing Olink® Explore HT – A New Era in Proteomics
Jun 28, 2023	Revealing the secrets of the human proteome with Olink® Insight: Exploring findings from one of the world's largest health studies
May 25, 2023	Olink to participate in June investor events
May 11, 2023	Olink reports first quarter 2023 financial results
Apr 17, 2023	Report from the Annual General Meeting of Olink Holding AB (publ) on 17 April 2023
Apr 13, 2023	Olink to report first quarter 2023 financial results on May 11, 2023
Mar 29, 2023	Swedish Olink technology enables further development of South African research and innovation
Mar 27, 2023	Olink publishes 2022 annual report
Mar 21, 2023	Bruno Rossi joins Olink as Chief Commercial Officer
Mar 15, 2023	Notice to attend the Annual General Meeting of Olink Holding AB (publ)
Mar 06, 2023	NUS Medicine implements Olink technology to accelerate precision medicine through next-generation proteomics
Feb 28, 2023	Olink establishes agreement with Regeneron Genetics Center to scale their proteomics efforts, potentially enabling a new era of drug discovery
Feb 21, 2023	Olink reports fourth quarter and full year 2022 financial results
Jan 18, 2023	Olink Holding AB (publ) announces pricing of public offering of American Depositary Shares